US Plasma Fractionation Market worth US$13.80 billion by 2028 with 6.4% CAGR | MarketsandMarkets™.
DELRAY BEACH, Fla., April 3, 2025 /PRNewswire/ -- The global US Plasma Fractionation Market is projected to reach US$13.80 billion by 2028 from US$10.13 billion in 2023, at a CAGR of 6.4% during the forecast period. The increasing use of immunoglobulins in a variety of therapeutic fields, as well as the market's players' strategic expansion of plasma collection centers and inventories, along with the rising incidence of respiratory diseases like alpha-1-antitrypsin deficiency (AATD) and Chronic obstructive pulmonary disease (COPD), are the main factors driving the market's expansion.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=93798284
Browse in-depth TOC on "US Plasma Fractionation Market"
150 - Tables
47 - Figures
140- Pages
By Based on Product, the US plasma fractionation market is segmented into protease inhibitors, coagulation factor concentrates, immunoglobulins, albumins, and other products. Immunoglobulins accounted for the largest share of the US plasma fractionation market in 2022. The dominance of this segment is mainly attributed to the rise in the cases of neurological and immunological diseases, the increase in off-label utilization of immunoglobulins, especially IVIg, and the increased usage of these immunoglobulins in the treatment of a variety of diseases and conditions that are linked to humoral immune deficiency or immune system dysfunction, including immune thrombocytopenic purpura, Kawasaki syndrome, Guillain-Barré syndrome, and graft-versus-host diseases after bone marrow transplantation. Additionally, the immunoglobins segment is anticipated to register the highest growth throughout the forecast period, based on volume. Owing to the broader range of medical indications, including autoimmune diseases, primary immunodeficiency disorders, neurological disorders, etc., and larger patient population served, IVIg typically contributes the most significant volume within the immunoglobulins segment of the US plasma fractionation market.
By Based on application, the US plasma fractionation market is segmented into pulmonology, hemato-oncology neurology, immunology, hematology, critical care, rheumatology, and other applications. In 2022, the pulmonology segment is expected to register the highest CAGR during the forecast period. The increasing demand for immunoglobulins to prevent and treat upper and lower respiratory tract infections due to their efficiency is a major factor driving growth in this market segment. Additionally, the use of protease inhibitors such as alpha-1-antitrypsin has also increased substantially over the past few years.
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=93798284
Key players in the US plasma fractionation market include ADMA Biologics (US), and Emergent BioSolutions (US).
Study Coverage
The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the US plasma fractionation market. A detailed analysis of the key industry players has been done to provide insights into their business overviews, products and services, key strategies, acquisitions, new product/service approvals, expansions, agreements, and recent developments associated with the US plasma fractionation market.
For more information, Inquire Now!
Related Reports:
Hematology Analyzers and Reagents Market
About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
In addition, MarketsandMarkets SalesIQ enables sales teams to identify high-priority accounts and uncover hidden opportunities, helping them build more pipeline and win more deals with precision.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
Share this article